Lung Cancer | Clinical

Thyroid Toxicity May Be Predictive of Immunotherapy Response in NSCLC

January 07, 2021

In an interview with Targeted Oncology, Vanessa Kazanietz, MD, discussed the findings from a study exploring the correlation between thyroid toxicity and response to immunotherapy as treatment of patients with metastatic non-small cell lung cancer.

FDA Grants Breakthrough Therapy to First Anti-TIGIT Therapy in NSCLC With High PD-L1

January 05, 2021

The FDA has granted a Breakthrough Therapy designation to tiragolumab in combination with atezolizumab for the frontline treatment of patients with metastatic non – small cell lung cancer whose tumors have high PD-L1 expression and no EGFR or ALK genomic aberrations.

Nivolumab Indication in Small Cell Lung Cancer Withdrawn from US Market

January 04, 2021

Bristol Myers Squibb has withdrawn the indication of nivolumab for the treatment of patients with small cell lung cancer who had disease progression after a platinum-based chemotherapy and at least 1 other line of therapy from the US market following a consultation with the FDA.

FDA Grants Frontline Lorlatinib Priority Review for ALK+ NSCLC

December 31, 2020

The FDA has accepted a supplemental New Drug Application for lorlatinib as a first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer and has granted the sNDA a Priority Review.

Advice for Testing Practices in Non-Small Cell Lung Cancer

December 31, 2020

Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses key takeaways on a presentation around managing non–small cell lung cancer cases in patients with contralateral lung nodules and dominant tumors.

RET, MET Inhibitors Advance Targeted Therapies in NSCLC

December 28, 2020

FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.